Plasmapp플라즈맵

Plasmapp's revenue fell again in 2025 and its losses remain deep, with the share price down about 55% over the past year.

Plasmapp is a Korean plasma technology company selling sterilizers and dental and orthopedic devices to hospitals and clinics in several countries. Its trailing twelve-month revenue is ₩12.0B against an operating loss of ₩7.1B, and its liabilities are well above equity. The share price has bounced 16% over the past month after a long decline from its 52-week high of ₩9,200.

What stands out

• Revenue has declined for three years, from ₩13.3B in 2022 to ₩8.5B in 2025, with an operating margin of -89.6% in 2025.
• Trailing twelve-month free cash flow is -₩8.7B, and cash of ₩2.5B sits against borrowings of ₩0.8B, so the company relies on outside funding to cover losses.
• Liabilities are about 13.7 times equity, and return on equity is -264.7% on a trailing basis.
• Recent filings include a rights offering decision and a third-party share allotment, both in July 2026, and the 5%+ holding reports show shareholder changes.
• Foreign ownership fell from 15.3% to 7.7% over the past 60 days, and foreign and retail investors were net sellers over the last 20 days.
• No news headlines were provided, so the reasons for recent share price moves are not covered in the data.

What to watch

• The half-year report for June 2026 was filed in August; the details of the rights offering and its effect on the share count are not in the data.
• Two exchange inquiries about news reports or price moves were filed in July 2026, and their outcome is not in the data.
• Whether revenue stabilizes and losses narrow, since the data shows no analyst forecasts or fair value estimate.